Physician profile
Thomas Roush
NPI 1942240965
$117,530.48
in general payments reported to CMS, 2019-2025
12 companies · $15K in 2025
The $15K reported for 2025 was more than what 90% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $14K · 2021: $12K · 2022: $18K · 2023: $33K · 2024: $15K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $41K · Consulting Fee: $18K · Food and Beverage: $3,313 · Travel and Lodging: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $40,683.26 |
| Consulting Fee | $17,850.00 |
| Food and Beverage | $3,313.40 |
| Travel and Lodging | $901.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $61,495.04 | 2019-2023 | Mlx, Simplify Cervical Artificial Disc |
| Globus Medical, INC. | $27,148.71 | 2024-2025 | Mlx |
| Centinel Spine, LLC | $23,963.20 | 2021-2023 | Prodisc L, Prodisc C, Prodisc C Vivo |
| Biotronik Nro, INC. | $2,465.61 | 2023-2025 | Prospera, Biotronik |
| Abbott Laboratories | $1,805.48 | 2021-2022 | |
| Acelrx Pharmaceuticals, INC. | $322.26 | 2020-2021 | |
| Medacta USA, INC. | $137.00 | 2025 | Nextar Spine Platform |
| Osteocentric Technologies, INC. | $73.38 | 2024 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Pfizer INC. | $40.79 | 2023-2025 | |
| Vertical Pharmaceuticals, LLC | $34.26 | 2023 | Dsuvia |
| Si-Bone, INC. | $22.63 | 2019 | |
| Heron Therapeutics, INC. | $22.12 | 2023 | Aponvie |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Roush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.